India, June 24 -- Immunic, Inc. (IMUX), a biotechnology company developing orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced Tuesday new, positive long-term open-label extension or OLE data from Phase 2 EMPhASIS trial of vidofludimus calcium (IMU-838) in relapsing-remitting multiple sclerosis or RRMS.
In the pre-market activity on the Nasdaq, Immunic shares were gaining around 3 percent.
The company's lead asset, vidofludimus calcium, is an orally administered investigational small molecule drug being developed for chronic inflammatory and autoimmune diseases. It is currently in late-stage clinical trials for multiple sclerosis.
The phase 2 EMPhASIS trial was an international, multi...